China has approved two domestically developed oral drugs for mildly symptomatic COVID-19 patients, the National Medical Products Administration said on Sunday.
The drugs, used to treat adult patients with mild to moderate COVID-19 infection, were developed by Simcere Pharmaceutical Group and a unit of Shanghai Junshi Biosciences Co Ltd, the administration said in a statement on its website. Is.